Artivion Inc. (AORT)
NYSE: AORT
· Real-Time Price · USD
28.89
0.12 (0.42%)
At close: May 13, 2025, 3:59 PM
28.68
-0.71%
Pre-market: May 14, 2025, 04:47 AM EDT
Artivion Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Aortic Stent Grafts Revenue | 123.08M | 107.47M | 63.9M | 57.36M | 48.05M | 50.1M | 44.83M | 37.04M | 34.23M |
| Aortic Stent Grafts Revenue Growth | +14.53% | +68.17% | +11.40% | +19.37% | -4.08% | +11.74% | +21.03% | +8.21% | n/a |
| On X Revenue | 83.98M | 74.53M | 8.32M | 8.13M | 179.3M | n/a | n/a | n/a | n/a |
| On X Revenue Growth | +12.69% | +795.98% | +2.27% | -95.46% | n/a | n/a | n/a | n/a | n/a |
| Other Products Revenue | 9.27M | 11.17M | 230.35M | 221.6M | n/a | n/a | n/a | n/a | n/a |
| Other Products Revenue Growth | -17.03% | -95.15% | +3.95% | n/a | n/a | n/a | n/a | n/a | n/a |
| Products Revenue | 290.23M | 261.19M | 65.38M | 70.71M | n/a | n/a | n/a | n/a | n/a |
| Products Revenue Growth | +11.12% | +299.49% | -7.54% | n/a | n/a | n/a | n/a | n/a | n/a |
| Surgical Sealants Revenue | 73.9M | 68.02M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Surgical Sealants Revenue Growth | +8.65% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 54.7M | 51.43M | 50.02M | 43.61M | 26.82M | 50.28M | 51.09M | 57.24M | 50.37M | 38.45M | 41.05M | 38.98M | 38.95M | 51.25M | 39.05M | 40.83M | 38.64M | 36.1M | 33.74M | 32.29M | 39M | 37.61M | 34.26M | 34.62M | 36.52M | 35.63M | 32.87M | 34.73M | 37.35M | 30.2M | 24.76M | 23.39M | 22.87M | 22.25M | 20.59M | 22.44M | 26.27M | 19.14M | 17.49M | 19.33M | 18.97M |
| Selling, General, and Administrative Revenue Growth | +6.37% | +2.82% | +14.69% | +62.60% | -46.65% | -1.60% | -10.74% | +13.65% | +30.97% | -6.33% | +5.30% | +0.07% | -23.99% | +31.24% | -4.35% | +5.67% | +7.02% | +6.99% | +4.51% | -17.21% | +3.70% | +9.78% | -1.05% | -5.19% | +2.50% | +8.39% | -5.34% | -7.02% | +23.69% | +21.97% | +5.84% | +2.26% | +2.81% | +8.03% | -8.22% | -14.61% | +37.28% | +9.40% | -9.48% | +1.89% | n/a |
| Research and Development Revenue | 6.73M | 7.4M | 6.61M | 7.5M | 6.95M | 7.64M | 6.42M | 7.42M | 7.22M | 8.3M | 11.8M | 8.65M | 10.13M | 9.46M | 9.97M | 8.36M | 7.75M | 6.57M | 5.75M | 5.52M | 6.36M | 5.31M | 6.26M | 5.84M | 5.55M | 6.78M | 5.22M | 5.72M | 5.37M | 6.36M | 4.28M | 4.73M | 4.09M | 3.84M | 3.71M | 3.28M | 2.61M | 2.54M | 2.96M | 2.68M | 2.25M |
| Research and Development Revenue Growth | -9.13% | +12.10% | -11.90% | +7.93% | -9.14% | +19.06% | -13.44% | +2.70% | -13.02% | -29.62% | +36.44% | -14.61% | +7.06% | -5.13% | +19.28% | +7.82% | +17.95% | +14.23% | +4.22% | -13.12% | +19.65% | -15.13% | +7.16% | +5.28% | -18.22% | +29.84% | -8.64% | +6.50% | -15.61% | +48.77% | -9.54% | +15.51% | +6.48% | +3.50% | +13.27% | +25.68% | +2.72% | -14.19% | +10.28% | +19.18% | n/a |